Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 21;25(31):4414-4426.
doi: 10.3748/wjg.v25.i31.4414.

Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment

Luísa Leite Barros  1 , Alberto Queiroz Farias  1 , Ali Rezaie  2
Affiliations
Review

Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment

Luísa Leite Barros et al. World J Gastroenterol. .

Abstract

Inflammatory bowel diseases (IBD), Crohn`s disease and ulcerative colitis, are chronic conditions associated with high morbidity and healthcare costs. The natural history of IBD is variable and marked by alternating periods of flare and remission. Even though the use of newer therapeutic targets has been associated with higher rates of mucosal healing, a great proportion of IBD patients remain symptomatic despite effective control of inflammation. These symptoms may include but not limited to abdominal pain, dyspepsia, diarrhea, urgency, fecal incontinence, constipation or bloating. In this setting, commonly there is an overlap with gastrointestinal (GI) motility and absorptive disorders. Early recognition of these conditions greatly improves patient care and may decrease the risk of mistreatment. Therefore, in this review we describe the prevalence, diagnosis and treatment of GI motility and absorptive disorders that commonly affect patients with IBD.

Keywords: Chronic intestinal pseudo-obstruction; Crohn’s disease; Dyssynergic defecation; Fecal incontinence; Gastrointestinal motility and absorptive disorders; Inflammatory bowel diseases; Irritable bowel syndrome; Small intestinal bacterial overgrowth; Small intestinal fungal overgrowth; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: This review was conducted without any financial support. LLB and AQF report not relevant conflict of interest. AR has served as a speaker and consultant and has received research grants from Bausch Health. AR has equity in Gemelli Biotech. Cedars-Sinai Medical Center has a licensing agreement with Bausch Health and Gemelli Biotech. AR has served as consultant for GutHub.

References

    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741–1755. - PubMed
    1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–1770. - PMC - PubMed
    1. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: Current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27. - PubMed
    1. Bryant RV, van Langenberg DR, Holtmann GJ, Andrews JM. Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status. J Gastroenterol Hepatol. 2011;26:916–923. - PubMed
    1. Teruel C, Garrido E, Mesonero F. Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther. 2016;7:78–90. - PMC - PubMed

MeSH terms